Close
Solutions
Online Inquiry
Global Services

scFv Generation from Hybridoma Cells

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

As a super provider of diverse antibodies, Creative Biolabs offers customers several approaches for scFv generation such as one-stop solution for developing CAR from Hybridoma, which is a very mature and useful technology for scFv construction.

scFv generation from Hybridoma cells

From vce.bioninja.com.au.

As we known, a variable region (Fv) always consists of a heavy chain variable region (VH) and a light chain variable region (VL), while a single-chain variable fragment (scFv) normally consists of a VH and a VL connected together via a peptide linker. Our seasoned scientists can generate a scFv from Hybridoma Cell Lines following this procedure: firstly, we immunize mice with the antigen, and then remove the spleen to get splenocytes (B cells). After the splenocytes and myeloma cells fusion step, hydridoma cell lines will be established for producing specific monoclonal antibodies. Our skilled scientists from Creative Biolabs can convert the Fv from full monoclonal antibody into a scFv, which can target the tumor antigen our customer interested in. Finally, we will clone this scFv, together with other CAR components into a Lentivirus vector for the future steps.

Creative Biolabs is a world leading expert in antibody engineering field, which can provide our clients with the best-class service in order to meet their research needs. Our years of experience guarantee we can offer you our high quality scFv generation.

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.